Clinical Trial Update: Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS Mutation [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating Onvansertib plus FOLFIRI and Bevacizumab for second-line metastatic colorectal cancer with KRAS mutation has completed and results ha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Onvansertib (onvansertib)

Snippet

Sponsor: Cardiff Oncology | Conditions: Metastatic Colorectal Cancer, KRAS Gene Mutation | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2025-03-04